AzurRx BioPharma Will Conduct Phase 2b Trial of MS1819 at TDN Clinical Sites
AzurRx BioPharma has been authorized to conduct its Phase 2b OPTION 2 clinical trial evaluating MS1819, its investigative therapy for...
AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cysti
On track to initiate the OPTION 2 trial by the end of Q2 2020 OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram...
AzurRx BioPharma Announces Promising Results from Trial Testing MS1819 for EPI in CF Patients
The investigational therapy MS1819 showed positive safety results in a Phase 2 clinical trial for the treatment of exocrine pancreatic...
Proteostasis Therapeutics Wins Big With FDA Decision
Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares made a solid gain on Wednesday after a key U.S. Food and Drug Administration (FDA)...
